POMT1 — Protein O-Mannosyltransferase 1

POMT1 — Protein O-Mannosyltransferase 1

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">POMT1 — Protein O-Mannosyltransferase 1</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>POMT1</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Protein O-Mannosyltransferase 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q34.13</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>Glycosyltransferase (ER Membrane Protein)</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>750 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~84 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>POMT1, MDDGA1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10585</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y6A6</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Muscle (skeletal)</td>
<td>Highest</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Function</td>
</tr>
<tr>
<td class="label">POMT2</td>
<td>O-mannosyltransferase partner</td>

POMT1 — Protein O-Mannosyltransferase 1

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">POMT1 — Protein O-Mannosyltransferase 1</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>POMT1</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Protein O-Mannosyltransferase 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q34.13</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>Glycosyltransferase (ER Membrane Protein)</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>750 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~84 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>POMT1, MDDGA1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10585</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y6A6</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Muscle (skeletal)</td>
<td>Highest</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Function</td>
</tr>
<tr>
<td class="label">POMT2</td>
<td>O-mannosyltransferase partner</td>
</tr>
<tr>
<td class="label">α-Dystroglycan</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">Dystrophin</td>
<td>Structural protein</td>
</tr>
<tr>
<td class="label">β-Dystroglycan</td>
<td>Dystroglycan complex</td>
</tr>
<tr>
<td class="label">Calnexin</td>
<td>ER chaperone</td>
</tr>
<tr>
<td class="label">BiP</td>
<td>ER chaperone</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-POMT1</td>
</tr>
<tr>
<td class="label">Small molecule</td>
<td>Chaperone therapy</td>
</tr>
<tr>
<td class="label">Enzyme replacement</td>
<td>Recombinant POMT1</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Gene + small molecule</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Muscle</td>
<td>Physical therapy, respiratory support</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Seizure management, developmental support</td>
</tr>
<tr>
<td class="label">Eye</td>
<td>Regular ophthalmologic evaluation</td>
</tr>
<tr>
<td class="label">Cardiac</td>
<td>Monitoring for cardiomyopathy</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

POMT1 (Protein O-Mannosyltransferase 1) encodes an endoplasmic reticulum enzyme that catalyzes the first step in the O-mannosylation of glycoproteins, a critical post-translational modification essential for proper protein function and cell surface interactions. Located on chromosome 9q34.13, POMT1 works in concert with POMT2 to catalyze the transfer of mannose from dolichol-phosphate-mannose to serine and threonine residues on target proteins. [@willer2002]

The most well-characterized substrate of POMT1 is alpha-dystroglycan (α-DG), a central component of the dystrophin-associated glycoprotein complex (DGC) that provides a critical link between the extracellular matrix and the cytoskeleton in muscle and brain tissues. Defects in POMT1 function cause abnormal glycosylation of α-DG, leading to a spectrum of congenital muscular dystrophies including Walker-Warburg syndrome (WWS), muscle-eye-brain disease (MEB), and limb-girdle muscular dystrophy type 2K (LGMD2K). [@beltran2004]

Gene Information

Protein Structure and Domain Architecture

POMT1 is a multipass transmembrane protein localized to the endoplasmic reticulum:

N-terminal ER Luminal Domain

• Contains the catalytic domain facing the ER lumen
• Contains multiple potential N-linked glycosylation sites
• Essential for interaction with POMT2

Transmembrane Regions

• Multiple hydrophobic transmembrane helices (10-12 predicted)
• Anchors the protein in the ER membrane
• Positions the catalytic domain correctly in the ER lumen

C-terminal Region

• Faces the cytosol
• Contains potential regulatory motifs
• May interact with other ER proteins

POMT1-POMT2 Complex

POMT1 must interact with POMT2 to form a functional enzyme complex:

• POMT1 provides the catalytic activity
• POMT2 stabilizes the complex and may regulate activity
• Both proteins are required for O-mannosyltransferase activity in vivo

Molecular Functions

O-Mannosylation Pathway

POMT1 catalyzes the first step in a unique glycosylation pathway:

Alpha-Dystroglycan Modification

The critical substrate for POMT1 is alpha-dystroglycan (α-DG):

• O-mannosylation: POMT1 adds the initial mannose to α-DG at specific serine/threonine residues
• Matriglycan formation:后续糖基化步骤产生一种独特的聚糖，称为matriglycan，能够与细胞外基质蛋白如层粘连蛋白、胶原蛋白和神经蛋白聚糖结合
• 受体功能：O-甘露糖基化的α-DG作为细胞外基质和肌动蛋白细胞骨架之间的桥梁

Other Substrates

POMT1可能对其他神经系统蛋白进行修饰：

• 神经元细胞粘附分子
• 细胞外基质蛋白
• 生长因子受体

Disease Associations

Walker-Warburg Syndrome (WWS)

POMT1突变是WWS最常见的原因之一，这是一种严重的先天性肌营养不良症：

临床特征：

• 严重的肌肉无力，从出生起就存在
• 先天性脑畸形（鹅卵石样无脑回）
• 眼睛异常（先天性白内障、视网膜发育不良）
• 癫痫发作
• 早期 lethality

• POMT1功能丧失导致α-DG甘露糖基化不足
• 异常α-DG无法与细胞外基质蛋白结合
• 影响肌肉和大脑发育

Muscle-Eye-Brain Disease (MEB)

POMT1突变还可导致MEB，这是一种略轻于WWS的表型：

临床特征：

• 先天性肌肉营养不良
• 眼睛异常（近视、白内障）
• 脑积水
• 癫痫发作
• 发育迟缓

Limb-Girdle Muscular Dystrophy Type 2K (LGMD2K)

较温和的POMT1突变可导致LGMD2K：

临床特征：

• 儿童期发病的进行性肌肉无力
• 跑步和爬楼梯困难
• 轻度认知障碍
• 病程进展较慢

CNS Involvement in Neurodegeneration

虽然POMT1主要与先天性肌营养不良相关，但其在神经系统的作用与神经退行性疾病有关：

• 神经迁移：α-DG的甘露糖基化影响神经细胞迁移
• 脑发育：POMT1功能影响皮层发育和神经元排列
• 血脑屏障：α-DG参与血脑屏障功能

Expression Pattern

POMT1在多种组织中表达：

在神经系统中，POMT1表达于：

• [神经元](/cell-types/神经元)：发育中的皮层神经元
• [神经干细胞](/cell-types/神经干细胞)：参与神经发生
• 星形胶质细胞：支持性胶质细胞
• 脑毛细血管：血脑屏障组成部分

Signaling Pathways

Interactions and Network

Protein-Protein Interactions

Pathway Connections

• Dystrophin-associated glycoprotein complex: Central to muscle integrity
• ER quality control: POMT1 folding and assembly
• Extracellular matrix signaling: Via α-DG-ligand interactions
• Wnt/β-catenin pathway: Possible crosstalk

Therapeutic Implications

Gene Therapy

• AAV-mediated POMT1 delivery: For correcting deficient O-mannosylation
• CRISPR-based approaches: Correcting pathogenic mutations
• mRNA delivery: Transient expression of functional POMT1

Small Molecule Approaches

• Chaperone therapy: Enhancing POMT1 folding and stability
• Substrate supplementation: Providing alternative glycosylation pathways
• Enzyme stabilization: Small molecule stabilizers

Protein Therapy

• Recombinant α-DG: Direct replacement of functional protein
• Engineered glycosyltransferases: Modified POMT1 with enhanced activity

Therapeutic Strategies

ER Stress and Cellular Quality Control

Unfolded Protein Response in POMT1 Deficiency

POMT1 deficiency triggers significant endoplasmic reticulum stress. The accumulation of improperly glycosylated proteins activates the unfolded protein response (UPR), an adaptive mechanism that initially attempts to restore ER homeostasis but can progress to apoptotic signaling if stress persists. In neurons, ER stress is particularly detrimental due to the cells' limited capacity to dilute accumulated damage through cell division.

The three major UPR pathways activated in POMT1-deficient cells include IRE1-mediated XBP1 splicing leading to chaperone expression, PERK-mediated eIF2α phosphorylation reducing protein translation and decreasing ER load, and ATF6-mediated transcription of ER chaperones and quality control components. Understanding these pathways provides targets for therapeutic intervention using pharmacological modulators of ER stress.

Protein Quality Control Mechanisms

Cells employ several quality control mechanisms to handle POMT1-related stress. ER-associated degradation (ERAD) targets misfolded proteins for ubiquitin-mediated degradation in the cytoplasm. Autophagy degrades protein aggregates and damaged organelles when ERAD is overwhelmed. Retrotranslocation exports proteins from the ER to the cytoplasm for degradation. These interconnected pathways determine cell survival or death in POMT1 deficiency.

Alpha-Dystroglycan at Synapses

Synaptic Function in the Central Nervous System

Alpha-dystroglycan (α-DG) is not just a component of the muscle membrane but also plays crucial roles at central nervous system synapses. In the brain, α-DG is enriched at postsynaptic densities where it interacts with extracellular matrix proteins like laminin and agrin. These interactions are essential for synaptic maturation, stability, and plasticity. Proper O-mannosylation of α-DG is required for these synaptic functions, explaining why POMT1 mutations can lead to cognitive deficits even in the absence of major structural brain abnormalities.

The role of POMT1 in synaptic plasticity encompasses long-term potentiation (LTP) formation for activity-dependent strengthening of synaptic connections, long-term depression (LTD) formation for activity-dependent weakening of synapses, dendritic spine morphology regulation of postsynaptic structure, and proper alignment of presynaptic and postsynaptic components.

Enzyme Biochemistry and Catalytic Mechanism

Active Site Architecture and Substrate Specificity

POMT1 possesses a catalytic domain facing the ER lumen. The enzyme uses dolichol-phosphate-mannose as the donor substrate and serine/threonine residues on acceptor proteins as the acceptor. The catalytic mechanism involves substrate binding for recognition of DPM and protein substrate, mannose transfer for catalytic transfer of mannose to protein, and product release for release of mannosylated protein and dolichol-phosphate.

The enzyme exhibits specificity for certain protein contexts, with α-DG being the primary known substrate in vivo. Understanding the substrate specificity and catalytic mechanism provides opportunities for developing small molecule modulators that can enhance residual enzyme activity in patients with partial loss-of-function mutations.

Kinetic Parameters and Structure-Function

POMT1 enzymatic activity can be characterized by Km values for both DPM and acceptor proteins, Vmax for maximum catalytic rate, and Kcat for turnover number. Disease-causing mutations often affect residues critical for substrate binding, catalytic activity, or complex formation with POMT2. Structural studies have identified the glycosyltransferase signatures and key catalytic residues required for enzyme function.

Animal Models

Mouse Models

• POMT1 knockout mice: Show embryonic lethality with severe muscle and brain defects
• Conditional knockout: Tissue-specific deletion reveals organ-specific functions
• knock-in models: Express disease-causing mutations

Zebrafish Models

• Morpholino knockdowns: Show muscle and brain developmental defects
• CRISPR mutants: Phenocopy human disease

Disease Models

• In vitro disease models: Patient-derived iPSCs differentiate into muscle and neuronal cells
• Organoid systems: Brain organoids to study CNS involvement

Recent Research Updates

Structure-Function Studies

Tan et al. (2009) elucidated the glycosyltransferase signatures of POMT1 and POMT2. The study identified key catalytic residues and structural features required for O-mannosyltransferase activity. Analysis of disease-causing mutations revealed that many affect residues critical for enzyme function or complex formation. This research provides a foundation for understanding how POMT1 mutations cause disease and for developing targeted therapies. [@tan2009]

Matriglycan Discovery

Yoshida-Moriguchi et al. (2009) discovered that the glycan attached by POMT1 and subsequent enzymes is matriglycan, a unique polysaccharide that binds to laminin and other extracellular matrix proteins. This work established the biochemical basis for α-DG function and explained how POMT1 deficiency leads to disease. The identification of matriglycan as the functional glycan has guided therapeutic development efforts. [@yoshida2009]

POMT1-POMT2 Coordination

Miao et al. (2015) demonstrated that POMT1 and POMT2 coordinate to catalyze O-mannosylation of α-dystroglycan. The study showed that both proteins form a functional complex in the ER membrane, with POMT1 providing catalytic activity and POMT2 acting as a stabilizing partner. Disruption of either component abolishes enzyme activity, explaining why mutations in either gene cause similar diseases. This research clarifies the molecular mechanism of POMT1 function. [@miao2015]

Cognitive Involvement

Ceral et al. (2017) investigated cognitive involvement in POMT1-related muscular dystrophy. The study found that patients with POMT1 mutations show variable degrees of cognitive impairment, from mild learning difficulties to severe intellectual disability. Brain imaging revealed structural abnormalities including cortical dysplasia and cerebellar hypoplasia. The degree of cognitive impairment correlated with the severity of muscle disease and the specific POMT1 mutation. This research highlights the CNS involvement in POMT1-related disorders. [@ceral2017]

Modeling POMT1 Disease

Larsson et al. (2020) generated patient-derived induced pluripotent stem cells (iPSCs) to model POMT1-related muscular dystrophy. Muscle cells differentiated from patient iPSCs showed reduced α-dystroglycan glycosylation and impaired laminin binding, phenocopying the disease. The model was used to test therapeutic approaches, including AAV-mediated POMT1 delivery, which restored α-DG function. This research provides a valuable platform for disease modeling and drug testing. [@larsson2020]

Gene Therapy Progress

Hernandez et al. (2023) advanced gene therapy approaches for POMT1-related muscular dystrophy. The study demonstrated that AAV-mediated delivery of POMT1 restored α-dystroglycan glycosylation in mouse models of the disease. Treatment improved muscle function and extended survival. The research identified optimal delivery routes and dosing regimens. Challenges remain regarding CNS delivery and immune responses. This represents significant progress toward clinical translation. [@hernandez2023]

CNS Implications

Chen et al. (2022) investigated how POMT1 deficiency affects brain development and wiring. Using mouse models and patient-derived cells, the study showed that POMT1 loss leads to impaired neuronal migration, abnormal cortical layering, and defective synapse formation. These defects result from abnormal α-dystroglycan glycosylation affecting extracellular matrix interactions during development. The research establishes that POMT1 has essential roles beyond muscle, directly affecting brain development. [@chen2022]

Clinical Implications

Diagnostic Considerations

• Genetic testing: Sequencing of POMT1 gene identifies pathogenic variants
• Biochemical testing: Analysis of α-DG glycosylation in muscle biopsy
• Prenatal testing: For families with known POMT1 mutations
• Newborn screening: Potential for early diagnosis

Biomarker Potential

• Serum CK: Elevated in POMT1-related muscular dystrophy
• α-DG glycosylation: Marker of therapeutic response
• Motor function assessments: Tracking disease progression

Management Strategies

Evolutionary Conservation

POMT1 is highly conserved across species:

• Humans: Full-length protein with all functional domains
• Mouse: 93% homology, functional conservation
• Zebrafish: Essential for muscle development
• Drosophila: Ortholog with preserved function

Summary

POMT1 encodes an essential ER glycosyltransferase that catalyzes the first step in O-mannosylation of glycoproteins, particularly α-dystroglycan. Mutations in POMT1 cause a spectrum of congenital muscular dystrophies ranging from severe Walker-Warburg syndrome to milder limb-girdle muscular dystrophy. The enzyme's function in brain development explains the CNS involvement seen in these disorders. Current research focuses on developing gene therapy and small molecule approaches to restore POMT1 function and improve patient outcomes.

See Also

• [POMT1 Protein](/proteins/pomt1-protein)
• [Alpha-Dystroglycan](/proteins/dystroglycan-protein)
• [Dystrophin Complex](/proteins/dystrophin-protein)
• [Walker-Warburg Syndrome](/diseases/walker-warburg-syndrome)
• [Muscular Dystrophy](/diseases/muscular-dystrophy)
• [Congenital Muscular Dystrophies](/mechanisms/congenital-muscular-dystrophies)

External Links

• [NCBI Gene: POMT1](https://www.ncbi.nlm.nih.gov/gene/10585)
• [UniProt: Q9Y6A6](https://www.uniprot.org/uniprot/Q9Y6A6)
• [GeneCards: POMT1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=POMT1)
• [OMIM: 607423](https://www.omim.org/entry/607423)

References